Bessemer Group
FSTX

Bessemer Group’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Bessemer Group’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-313
Closed -$11K – 1936
2017
Q1 		$11K Hold
313
– – ﹤0.01% 1527
2016
Q4 		$10K Buy
+313
New +$11.5K ﹤0.01% 1645

Other funds holding FSTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Bessemer Group's FSTX Position: Q2 2017 in Review

Bessemer Group sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q2 2017, closing a stake of 313 shares — an estimated $11K sold.

Bessemer Group first reported a position in FSTX in Q4 2016 and held it in 2 quarters. The position peaked at $11K in Q1 2017. 33 funds tracked by Wall St. Rank hold FSTX as of Q2 2017.

  • Bessemer Group reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Bessemer Group sold 313 F-star Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $11K.
  • Bessemer Group first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2016 and held it in 2 quarters.
  • Bessemer Group's F-star Therapeutics, Inc. Common Stock position peaked at $11K in Q1 2017.
  • 33 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Bessemer Group's 13F filing for Q2 2017, filed 28 Jul 2017.